Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy

BACKGROUND: Aberrant activation of the MET receptor in cancer is sustained by genetic alterations or, more frequently, by transcriptional upregulations. A fraction of MET-amplified or mutated tumors are sensible to MET targeting agents, but their responsiveness is typically short-lasting, as seconda...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiriaco, Cristina, Donini, Chiara, Cortese, Marco, Ughetto, Stefano, Modica, Chiara, Martinelli, Ilaria, Proment, Alessia, Vitali, Letizia, Fontani, Lara, Casucci, Monica, Comoglio, Paolo Maria, Giordano, Silvia, Sangiolo, Dario, Leuci, Valeria, Vigna, Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585715/
https://www.ncbi.nlm.nih.gov/pubmed/36271379
http://dx.doi.org/10.1186/s13046-022-02479-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585715/
https://www.ncbi.nlm.nih.gov/pubmed/36271379
http://dx.doi.org/10.1186/s13046-022-02479-y

Ejemplares similares